Dr Kevin Sun



Kevin (Xueying) Sun is a trained Chinese surgeon who has embraced his passion for medical research. He began work with A/Professor Geoffrey W Krissansen at Department of Molecular Medicine & Pathology in 1998, initially supported by a World Health Organization Fellowship. Then he obtained the support of the Wellcome Trust (UK) in the form of a Wellcome Trust Research Leave Fellowship, which enabled him to spend two years in Auckland, followed by a further two years at universities in China, where he was able to establish his own laboratory. He returned to Auckland and joined the team of Cellular & Molecular Biology led by A/Professor Geoffrey W Krissansen as a member of the Lactopharma consortium in 2005. He is also holding positions of specially invited professor at Harbin Medical University and visiting professor at Shandong University in China. He is a member of Editorial Board of "World Journal of Gastroenterology", "Liver Cancer Review Letters", and "World Journal of Gastrointestinal Pharmacology and Therapeutics",and reviewers of over ten journals and three foundations including National Natural Scientific Foundation in China.

His main research interest is to seek potential strategies to strengthen conventional treatments for cancers especially liver cancer by targeting tumour angiogenesis, hypoxia and immunity. With surgical skills and medical background, he is skilful at various animal models. Working with A/Professor Geoffrey W Krissansen and collaborating with researchers at Hong Kong University, he established several animal models including disseminated liver metastatic tumours, intraportal delivery of associated adenoviral particles, and disseminated liver and lung metastases of 4T1 breast and CT26 colon cancers. At his own lab in China, he established subcutaneous H22 and HeGP2 hepatoma in mice, orthotopic CBRH7919 hepatoma in rats, and transcatheter arterial embolization for liver cancer using DSA in rats. More recently, in a collaborative research project with Professor Bill Wilson at ACSRC, he established models of orthotopic HepG2 hepatoma and hepatic hypoxia induced by ligation of hepatic artery in mice. In addtion, he has been seeking potential reagents especially extracts from Chinese herbs to attenuate ischemia reperfusion-induced organ injury or induce immune tolerance to transplants.

Selected publications and creative works (Research Outputs)

  • Li, W., Dong, X., He, C., Tan, G., Li, Z., Zhai, B., ... Jiang, H. (2019). LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. Journal of experimental & clinical cancer research : CR, 38 (1)10.1186/s13046-019-1177-0
  • Leng, K., Xu, Y., Kang, P., Qin, W., Cai, H., Wang, H., ... Li, Z. (2019). Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway. Cell death & disease, 10 (4)10.1038/s41419-019-1506-4
  • Jiang, X., Zhang, C., Li, W., Jiang, D., Wei, Z., Lv, M., ... Sun, X. (2019). PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer. Oncology reports, 41 (3), 1949-1959. 10.3892/or.2018.6934
  • Zhai, B., Ren, H.-Y., Li, W.-D., Reddy, S., Zhang, S.-J., & Sun, X.-Y. (2019). Castleman disease presenting with jaundice: A case report and review of literature. WORLD JOURNAL OF CLINICAL CASES, 7 (3), 373-381. 10.12998/wjcc.v7.i3.373
  • Ma, L., Zhai, B., Zhu, H., Li, W., Jiang, W., Lei, L., ... Sun, X. (2019). The miR-141/neuropilin-1 axis is associated with the clinicopathology and contributes to the growth and metastasis of pancreatic cancer. Cancer Cell International, 1910.1186/s12935-019-0963-2
  • Li, Z. Y., & Sun, X. Y. (2018). Molecular targets regulating invasion and metastasis of pancreatic cancer. World Chinese Journal of Digestology, 26 (28), 1651-1659. 10.11569/wcjd.v26.i28.1651
  • Li, Z., Zhao, F., Cao, Y., Zhang, J., Shi, P., Sun, X., ... Tong, L. (2018). DHA attenuates hepatic ischemia reperfusion injury by inhibiting pyroptosis and activating PI3K/Akt pathway. European journal of pharmacology, 835, 1-10. 10.1016/j.ejphar.2018.07.054
  • Jiang, W., Li, G., Li, W., Wang, P., Xiu, P., Jiang, X., ... Jiang, H. (2018). Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways. Scientific reports, 8 (1)10.1038/s41598-018-28010-y

Contact details

Alternative contact


Primary office location

M&HS BUILDING 502 - Bldg 502
Level 3, Room 301
New Zealand